Novartis Scemblix® shows superior major molecular response
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for...
Source: globenewswire.com
Durable Responses News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Durable Responses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Durable Responses Today - Breaking & Trending Today
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
SEATTLE, Dec. 05, 2023 -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to...
Source: marketscreener.com
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance...
Source: marketscreener.com
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the
Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populationsOral presentations highlighting new findings from a clinical trial of epcoritamab in patients with relapsed/refractory (R/R) dif...
Source: pharmiweb.com
Daiichi Sankyo : ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors(414.1KB
Press Release ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors ... | June 5, 2023
Source: marketscreener.com